Norcal Medical Research, Inc.

04/01/2026

The next few months NorCal will be focused on three exciting NEW WEIGHT LOSS STUDIES studies involving unique medications being developed to provide additional treatment options for (1) individuals with overweight condition and Type 2 diabetes (current) as well as (2) for persons without diabetes (May), and (3) for those with Type 1 diabetes (July)!

Read our April newsletter to find out more and/or contact us at 415-461-1585 for additional info and to see if you may qualify.

Email from NORCAL Medical Research Linda M. Gaudiani MD   Possibilities today...Treatments Tomorrow APRIL 2026   Greetings friends of NorCal! Welcome to NorCal’s April 2026 newsletter. I continue to b

02/23/2026

Interested in LOSING WEIGHT? The newest weight loss medications? Life style strategies for optimizing your health?

NorCal Medical Research studies the latest medications for sustainable, safe weight loss in adults without diabetes and in persons with Type 1 and Type 2 Diabetes!

Participants receive:
• Free metabolic screening, blood tests, EKGs, body composition studies and more
• Access to study weight loss medications at no cost
• Life style support and dietary coaching
• Meticulous study-related care and monitoring from medical experts
• Compensation for time and travel
• Coordination with your primary practitioners

Let us give you more info at: 📞 415-461-1585 📧 info@norcalmedicalresearch.com 🌐 NorCalMedicalResearch.com Linda M Gaudiani MD FACP FACE Medical Director

NorCal conducts clinical research in the North SF Bay Area and is enrolling patients in weight loss, diabetes, neuropathy and thyroid studies. We have extensive experience in state-of-the-art clinical research with leading pharmaceutical companies.

02/11/2026

NorCal is excited to be enrolling patients in a new clinical trial for eloralintide, a long-acting form of the hormone amylin which has benefits similar to the GLP-1s. We are also now offering free metabolic screening including free HA1C, finger stick blook sugar tests and more for anyone concerned about their risk of prediabetes or diabetes.

For more details, check out our February newsletter and contact us at 415-461-1585 with any questions or to make an appointment.

Email link

Email from NORCAL Medical Research Linda M. Gaudiani MD   Possibilities today...Treatments Tomorrow FEBRUARY 2026   Greetings friends of NorCal! Welcome to our February 2026 newsletter. Starting immed

01/25/2026

THYROID CLINICAL STUDY ENDING ON JANUARY 30!!!
Have you thought about exploring a safe thyroid replacement therapy other than the standard levothyroxine you may be taking now?
The study compares naturally derived thyroid replacement therapy as Armour thyroid to synthetic levothyroxine for individuals with hypothyroidism. Armour is made from purified thyroid extract and contains both T4 and T3 thyroid hormones.
Call us right away at 415-461-1585 to find out more details about the study while there is still time to enroll.

10/28/2025

Our FALL newsletter highlights exciting clinical trials for weight loss and hypothyroidism. We're currently recruiting participants for a study on eloralintide, a promising new weight loss drug for persons with type 2 diabetes, and exploring alternative thyroid treatments. Call us at 415.461.1585 to learn more about our studies and how you can participate.

https://conta.cc/46RF3Qv

10/11/2025

New weight loss study for people with Type 2 Diabetes! Call 415-461-1585 for details!

08/18/2025

NorCal is conducting a clinical trial to compare Armour desiccated animal thyroid with synthetic levothyroxine for treatment of hypothyroidism. If you have hypothyroidism and are on a stable daily dose of levothyroxine, you may qualify to participate. To learn more about our study check out our August newsletter.

Contact us at 415-461-1585 or info@norcalmedicalresearch.com.



https://conta.cc/4n9hJTR

Email from Linda M. Gaudiani MD   Possibilities today...Treatments Tomorrow AUGUST 2025   If you know someone who might benefit from this newsletter, please forward it to them! Greetings friends of N

06/10/2025

We just published our summer newsletter! Find out about our new weight loss study for persons with type 2 diabetes: it is testing a new ORAL GLP-1 medication to help with weight loss and HA1C lowering. Our medical director also discusses one of her favorite topics: the importance of nutritional and lifestyle counseling when losing weight. https://conta.cc/447i6r0

06/04/2025

We are now doing a clinical trial of a NEW ORAL WEIGHT LOSS MEDICATION to study its effects on lowering HA1C in overweight persons with type 2 diabetes. If your HA1C is over 7% call us to see if you qualify!

05/03/2025

Great news! We are extending enrollment for our weight loss study targeting individuals with type 2 diabetes and A1C >7%. This study evaluates the effectiveness of tirzepatide combined with long-acting receptor amylin. Join us in advancing healthcare through clinical research.

https://conta.cc/3RJOTf5

05/01/2025

We are currently enrolling patients in clinical studies for weight loss and A1C lowering for persons with Type 2 Diabetes. Call us to see if you might qualify!

Linda Gaudiani, MD FACE FACP - Medical Director
Elizabeth Lowe,MD
Irene Teper, MD

03/28/2025

Our March/April Newsletter is out! Find out about our currently enrolling diabetes/obesity and thyroid studies, and the latest news about GLP-1s, including the shift in how obesity is now treated and perceived, the incredible efficacy of GLP1 medications like Tirzepatide and recent developments in the availabilty of compounded GLP1s.

Contact us with any questions at 415.461.1585 or info@norcalmedicalresearch.com

Email from NORCAL Medical Research Linda M. Gaudiani MD   Possibilities today...Treatments Tomorrow MARCH/APRIL 2025   If you know someone who might benefit from this newsletter, please forward it to